bullish
Quiddity Leaderboard SE600 Dec 23: 7 Changes Possible Including Two Intra-Review Changes
482 Views26 Sep 2023 18:50
If the Dechra Pharma and Chr Hansen deals close prior to the Dec 23 review, there will be intra-review replacements. Synthomer and Adevinta are currently leading the race to occupy these slots.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
- Quiddity Leaderboard ES50 Sep 24: The Race For Europe's Multi-Billion Dollar Index Flows16 Nov 2023
- Quiddity Leaderboard SE600 Dec 23: 6 ADDs/DELs and Two Intra-Review Changes Possible15 Nov 2023
- Quiddity Leaderboard SE600 Dec 23: Novartis-Sandoz, Dechra, CHR, and Others19 Oct 2023
- Quiddity Leaderboard SE600 Dec 23: 7 Changes Possible Including Two Intra-Review Changes26 Sep 2023
- Quiddity Leaderboard TDIV Dec 23: Many Changes and One-Way Flows of US$1.2bn+!25 Sep 2023
- Quiddity Leaderboard ASX Dec 23: 5 ASX 200 Changes and Other Large Potential Flow Events (NCM, AKE)20 Sep 2023
- TOPIX Inclusions: Who Is Ready (Sep 2023)11 Sep 2023
x